Delving into the Latest Updates on Allergan Pharma Co. with Synapse

概览

排名前五的药物类型	数量

小分子化药	1

排名前五的靶点	数量

δ opioid receptor x κ opioid receptor x μ opioid receptor	1

关联

1

项与 Allergan Pharma Co. 相关的药物

Eluxadoline

艾沙度林

靶点

δ opioid receptor x κ opioid receptor x μ opioid receptor

作用机制

δ opioid receptor拮抗剂 [+2]

在研机构

原研机构

在研适应症

非在研适应症

最高研发阶段批准上市

首次获批国家/地区

美国

首次获批日期2015-05-27

100 项与 Allergan Pharma Co. 相关的临床结果

登录后查看更多信息

0 项与 Allergan Pharma Co. 相关的专利（医药）

登录后查看更多信息

19

项与 Allergan Pharma Co. 相关的文献（医药）

2001-08-01·Microscopy and Microanalysis

Computer Assisted Morphometry: A Pathologist’s Perspective

作者: Holland, JM ; Holland, J.M.

AbstractIn spite of improved equipment and software, the routine application of quantitative microscopy to practical problems in drug development has been limited. This is due to a perceived and often real increase in project complexity and time added by quantitation of tissue changes, without an offsetting return of information. A major barrier to quantitative microscopy is the degree of difficulty in collecting data. The more steps in this process, the less attractive the task. Therefore, it follows that the more automated the task, the more likely quantitative methods will be applied. The purpose of this presentation will be to illustrate an approach taken to automate the morphometric quantification of muscle atrophy which follows dennervation.The traditional morphometric approach to assess myofiber atrophy is based upon laborious planometric measurement of individual muscle fiber cross-sections. Examples of the type of data obtained using the traditional method are shown in text table 1.

1998-11-10·Proceedings of the National Academy of Sciences1区 · 综合性期刊

Retinoic acid alters the intracellular trafficking of the mannose-6-phosphate/insulin-like growth factor II receptor and lysosomal enzymes

1区 · 综合性期刊

Article

作者: Chandraratna, Roshantha A. S. ; Bell, Jennifer ; Beard, Richard L. ; Kang, Jing X. ; Leaf, Alexander

Previously, we showed that retinoic acid (RA) binds to the mannose-6-phosphate/insulin-like growth factor II receptor (M6P/IGF2R) with high affinity, suggesting that M6P/IGF2R may be a receptor for RA. Here, we show that RA, after 2–3 h of incubation with cultured neonatal-rat cardiac fibroblasts, dramatically alters the intracellular distribution of M6P/IGF2R as well as that of cathepsin B (a lysosomal protease bearing M6P). Immunofluorescence techniques indicate that this change in intracellular distribution is characterized by a shift of the proteins from the perinuclear area to cytoplasmic vesicles. The effect of RA was neither blocked by an RA nuclear receptor antagonist (AGN193109) nor mimicked by a selective RA nuclear-receptor agonist (TTNPB). Furthermore, the RA-induced translocation of cathepsin B was not observed in M6P/IGF2R-deficient P388D1 cells but occurred in stably transfected P388D1 cells expressing the receptor, suggesting that the effect of RA might be the result of direct interaction with M6P/IGF2R, rather than the result of binding to the nuclear receptors. These observations not only support the idea that M6P/IGF2R mediates an RA-response pathway but also indicate a role for RA in control of intracellular trafficking of lysosomal enzymes. Therefore, our observations may have important implications for the understanding of the diverse biological effects of retinoids.

1995-07-01·Drug metabolism and disposition: the biological fate of chemicals

Comparative ocular pharmacokinetics of brimonidine after a single dose application to the eyes of albino and pigmented rabbits.

Article

作者: Tang-Liu, D D ; Acheampong, A A ; Shackleton, M

Brimonidine is a potent ocular hypotensive drug. The ocular pharmacokinetics of 14C-brimonidine in albino and pigmented rabbits were compared after ocular instillation of a 35-microliters drop of a 0.5% 14C-brimonidine solution. Ocular drug and metabolite concentrations were measured as total radioactivity and by a selective HPLC method. Rapid ocular absorption resulted in peak drug concentrations in aqueous humor of 2.16 +/- 0.75 micrograms/ml (mean +/- SD) and 1.52 +/- 0.38 micrograms/ml at 0.67 hr postdosing in albino and pigmented rabbits, respectively. Drug elimination from aqueous humor was rapid initially with a half-life of 1 hr in rabbits, followed by a slower decline phase in pigmented rabbits. Radioactivity concentration in iris-ciliary body of albino rabbit reached a peak of 5.04 micrograms-eq/g at 40 minutes and declined to 0.10 micrograms-eq/g at 6 hr postdosing with a half-life of 1 hr. The radioactivity concentrations in pigmented iris-ciliary body rose to a peak of 20.1 micrograms-eq/g at 1.5 hr and stayed relatively steady for at least 4 hr before declining slowly to 0.43 micrograms-eq/g 90 days postdose. The terminal half-life of brimonidine in pigmented iris-ciliary body was 160 hr. Three metabolites were detected in the conjuctiva and iris-ciliary body, and brimonidine was the major drug-related substance in aqueous humor and iris-ciliary body. The results indicate that brimonidine is absorbed rapidly into rabbit eyes, metabolized in ocular tissues, and has significant affinity for melanin-containing tissues.(ABSTRACT TRUNCATED AT 250 WORDS)

100 项与 Allergan Pharma Co. 相关的药物交易

登录后查看更多信息

100 项与 Allergan Pharma Co. 相关的转化医学

登录后查看更多信息